
Pharmaceutical Executive
Researchers at the Massachusetts Institute of Technology (MIT) have devised a novel drug capsule coated with tiny needles to deliver large-molecule biopharmaceuticals.

Pharmaceutical Executive
Researchers at the Massachusetts Institute of Technology (MIT) have devised a novel drug capsule coated with tiny needles to deliver large-molecule biopharmaceuticals.

Pharmaceutical Executive
With more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before.

Pharmaceutical Executive
Lurking in the shadows of the US General Elections is something called The Sequestration Transparency Act of 2011.

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive
Companies gain support-and pressure-to deliver new treatments for spreading outbreak.

Pharmaceutical Executive
Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training.

Pharmaceutical Executive
An escalating political debate over pharma pricing and reimbursement nears the boiling point.

Pharmaceutical Executive
In the wake of last week’s declaration by new HHS Secretary, Sylvia Burwell, that “Obamacare is working”, it’s probably time for American Rx product managers and marketers to step back and consider where we have travelled since January 1st of this year.

Pharmaceutical Executive
In a bit of good news for pharma, Moody’s Investors Service has upgraded its outlook for the global pharmaceutical industry to stable.

Pharmaceutical Executive
Successfully commercializing a proprietary drug in China can be a Kafkaesque affair.

Pharmaceutical Executive
The UK’s Medicines and Healthcare Regulatory Authority (MHRA) has awarded Northwest Biotherapeutics, Inc. (Bethesda, MD) the very first “Promising Innovative Medicine”, or PIM designation, for the company’s DCVax-L product.

Pharmaceutical Executive
This month’s ePatient Connections Summit in Philadelphia, PA, saw biopharmaceutical firms, medical device companies, and patient advocates discuss best practices for engaging patients online and in social media settings.

Pharmaceutical Executive
FDA’s Center for Drug Evaluation and Research is establishing an Emerging Technology Team (ETT) to assist innovative manufacturers in navigating the regulatory process and “overcoming roadblocks”.

Pharmaceutical Executive
The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Canada’s Research-Based Pharmaceutical Companies (Rx&D) have welcome finalization of the text for the Comprehensive Economic and Trade Agreement (CETA).

Pharmaceutical Executive
Hemispherx Biopharma (Philadelphia, PA) has announced a set of research collaborations designed to develop “therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation”.

Pharmaceutical Executive
Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).

Pharmaceutical Executive
Scary tales of The-Next-Big-Social-Thing killing off the first digital marketing blockbuster have been building for years. McKinsey’s November 2013 iConsumer survey reported a 20 percent decline in email usage between 2008 and 2012, as the medium gave up ground to social networks and mobile messaging apps.

Pharmaceutical Executive
The European Medicines Agency (EMA) is reviewing available information on Ebola treatments currently under development to “facilitate evidence-based decision-making” by health authorities.

Pharmaceutical Executive
The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”.

Pharmaceutical Executive
The Non-Hodgkin Lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia, China and Japan will expand from $1.1 billion in 2013 to $1.7 billion by 2020, with Japan remaining the largest contributor to growth, according to GBI Research.

Pharmaceutical Executive
Although biopharmaceutical companies and regulatory authorities have made considerable progress in establishing policies for bringing biosimilars to market, key differences and gaps in requirements for testing and documenting product similarity still characterize the European Union, the U.S. and other regions.

Pharmaceutical Executive
What can be gleaned about the direction that health policy will take for the next five years under the new European Commission, scheduled to take office at the beginning of November? Peter O’ Donnell address this question in his new Applied Clinical Trials column here.

Pharmaceutical Executive
Merck KGaA has announced that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion.

Pharmaceutical Executive
After almost two years of discussion and analysis, the Food and Drug Administration is finalizing a proposal for collecting data from manufacturers to help measure the performance of manufacturing operations and the quality of resulting drugs and biologics

Pharmaceutical Executive
Although it is true that there are many legitimate ways to succeed, a host of these strategies appear to be diametrically opposite of one another: Diversified versus pure play, generic versus ethical, regional versus global, R&D versus limited R&D, organic development versus acquisitions, and so on.

Pharmaceutical Executive
A second payment has now been made under the UK’s Pharmaceutical Price Regulation Scheme (PPRS).

Pharmaceutical Executive
Up until a few months ago, there was little industry interest or public support for developing vaccines and treatments to combat the Ebola virus.

Pharmaceutical Executive
Pharmacovigilance controls are becoming firmly embedded in the European Union’s post-authorization regulatory system, with the European Medicines Agency (EMA) acting as the pivot for an EU-wide network of agencies monitoring medicines throughout their market lifespan.

Pharmaceutical Executive
The European Federation of Pharmaceutical Industries and Associations’ new medicines verification system will put an end to the re-sale of stolen and counterfeit drugs in the European supply chain, the organisation claims.